Vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. It is rarely possible to achieve equally good results with single agent treatment. Thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). See DOSAGE AND ADMINISTRATION for possible increased toxicity when used in combination therapy. It has been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, Wilm's tumour, osteogenic sarcoma, mycosis fungoides, Ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung, and gynaecological tumours of childhood, In recent years, multiple-agent regimens have been developed for the treatment of a variety of malignant disorders in children. Paediatric patients with neuroblastoma, osteogenic sarcoma, Ewing's sarcoma, rhabdomyosarcoma, Wilm's tumour, Hodgkin's disease, non-Hodgkin's lymphomas, embryonal carcinoma of the ovaries, and rhabdomyosarcoma of the uterus should be considered candidates for such polychemotherapy treatment. Close co-operation among oncologists, paediatricians, radiologists and surgeons is required to achieve the best possible results. Patients with true idiopathic thrombocytopenic purpura refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to vincristine sulfate, but the drug is not recommended as primary treatment for this disorder. Recommended weekly doses of vincristine sulfate given for 3 to 4 weeks have produced permanent remissions in some patients. If patients fail to respond after 3 to 6 doses, it is unlikely that there will be any results with additional doses.
How to take it
The way to take this medicine is: Intravenous.
This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
Store at 2 to 8 degrees Celsius
Protect from Light
Refrigerate
Do not Freeze
Shelf lifetime is 2 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
A clear colourless solution free from particulate matter.
Do I need a prescription?
These medicine packs are available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
1mgx1mL pack
2mgx2mL pack
5x2mg/2mL pack
We are unable to tell you if you need a prescription for these medicines. You can ask your pharmacist. This medicine is
Not Scheduled.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. It is rarely possible to achieve equally good results with single agent treatment. Thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). See DOSAGE AND ADMINISTRATION for possible increased toxicity when used in combination therapy. It has been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, Wilm's tumour, osteogenic sarcoma, mycosis fungoides, Ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung, and gynaecological tumours of childhood, In recent years, multiple-agent regimens have been developed for the treatment of a variety of malignant disorders in children. Paediatric patients with neuroblastoma, osteogenic sarcoma, Ewing's sarcoma, rhabdomyosarcoma, Wilm's tumour, Hodgkin's disease, non-Hodgkin's lymphomas, embryonal carcinoma of the ovaries, and rhabdomyosarcoma of the uterus should be considered candidates for such polychemotherapy treatment. Close co-operation among oncologists, paediatricians, radiologists and surgeons is required to achieve the best possible results. Patients with true idiopathic thrombocytopenic purpura refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to vincristine sulfate, but the drug is not recommended as primary treatment for this disorder. Recommended weekly doses of vincristine sulfate given for 3 to 4 weeks have produced permanent remissions in some patients. If patients fail to respond after 3 to 6 doses, it is unlikely that there will be any results with additional doses.
How to take it
The way to take this medicine is: Intravenous.
This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
Store at 2 to 8 degrees Celsius
Do not Freeze
Protect from Light
Refrigerate
Shelf lifetime is 2 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
A clear colourless solution free from particulate matter.
Do I need a prescription?
These medicine packs are available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
5x1mg/1mL pack
We are unable to tell you if you need a prescription for these medicines. You can ask your pharmacist. This medicine is
Not Scheduled.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. It is rarely possible to achieve equally good results with single agent treatment. Thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). See DOSAGE AND ADMINISTRATION for possible increased toxicity when used in combination therapy. It has been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, Wilm's tumour, osteogenic sarcoma, mycosis fungoides, Ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung, and gynaecological tumours of childhood, In recent years, multiple-agent regimens have been developed for the treatment of a variety of malignant disorders in children. Paediatric patients with neuroblastoma, osteogenic sarcoma, Ewing's sarcoma, rhabdomyosarcoma, Wilm's tumour, Hodgkin's disease, non-Hodgkin's lymphomas, embryonal carcinoma of the ovaries, and rhabdomyosarcoma of the uterus should be considered candidates for such polychemotherapy treatment. Close co-operation among oncologists, paediatricians, radiologists and surgeons is required to achieve the best possible results. Patients with true idiopathic thrombocytopenic purpura refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to vincristine sulfate, but the drug is not recommended as primary treatment for this disorder. Recommended weekly doses of vincristine sulfate given for 3 to 4 weeks have produced permanent remissions in some patients. If patients fail to respond after 3 to 6 doses, it is unlikely that there will be any results with additional doses.
How to take it
The way to take this medicine is: Intravenous.
This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
Store at 2 to 8 degrees Celsius
Protect from Light
Refrigerate
Do not Freeze
Shelf lifetime is 2 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
A clear colourless solution free from particulate matter.
Do I need a prescription?
These medicine packs are available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
1mgx1mL pack
2mgx2mL pack
5x2mg/2mL pack
We are unable to tell you if you need a prescription for these medicines. You can ask your pharmacist. This medicine is
Not Scheduled.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
